Thursday, June 08, 2023
Single Cell Discoveries, a Contract Research Organization (CRO) specializing in single-cell sequencing, has proudly announced the introduction of the Illumina NovaSeq X Plus sequencing system in the Benelux region. This marks a significant achievement for Single Cell Discoveries as they strive to drive innovation and provide valuable insights to biopharmaceutical companies, health systems, and academic research centers worldwide.
The Illumina NovaSeq X Plus sequencing system represents a notable advancement in high-throughput sequencing, enabling Single Cell Discoveries to unlock new opportunities for their clients. It is the fastest, most powerful, and sustainable high-throughput sequencer available, capable of generating more than 20,000 whole genomes per year at a cost of $200 per genome.
Mauro Muraro, CEO of Single Cell Discoveries, expressed his enthusiasm for the delivery, stating, "We are excited to incorporate the Illumina NovaSeq X Plus sequencing system into our advanced infrastructure. This demonstrates our dedication to providing our clients with the most innovative tools and services in the single-cell field. With the NovaSeq X Plus system, we are better equipped than ever to ensure fast turnaround times and excellent quality throughout the single-cell workflow."
Bas Verhoef, Head of Europe at Illumina, commented on the NovaSeq X series, saying, "Our technology can deliver 2.5 times greater throughput while reducing sequencing costs. This revolutionary advancement will enhance Single Cell Discoveries' ability to provide rapid turnaround times and process large sample volumes."
Single Cell Discoveries' investment in the Illumina NovaSeq X Plus sequencing system exemplifies their ongoing commitment to pushing the boundaries of single-cell sequencing. By leveraging this state-of-the-art technology, Single Cell Discoveries aims to accelerate the development of precision medicine, contribute to the understanding of complex diseases, and foster groundbreaking research initiatives across Europe and beyond.
